Neogen Chemicals
Neogen Chemicals Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: order book.
The short version
Base business revenue expected to cross INR 1,000 crore in FY27 with 10-15% growth projected for FY28, targeting INR 1,100-1,200 crore. Revenue Growth**: Base business expected to grow from INR 950-1,050 crore in FY27 to INR 1,100-1,200 crore in FY28, with 10-15% increase focused on stabilizing and optimizing operations.
From Neogen Chemicals's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Base business revenue expected to cross INR 1,000 crore in FY27 with 10-15% growth projected for FY28, targeting INR 1,100-1,200 crore.
- Optimization focus in FY28 on margins, working capital, and product mix, emphasizing larger volume molecules to improve efficiency.
- Battery chemicals business anticipated to reach INR 300 crore revenue in FY27, mainly from salts (~INR 200 crore) and electrolyte (~INR 100 crore).
- FY28 battery chemicals revenue expected to exceed INR 1,000 crore with 70-80% salt utilization and 30-50% electrolyte utilization.
- By FY29, full capacity utilization is targeted for both base and battery businesses, potentially generating INR 2,400-2,900 crore revenue from local electrolyte and international salt business.
- Working capital cycle expected to improve from 140-160 days to 110-120 days as business scales and larger molecules dominate.
- Continuous growth with focus on operational optimization and working capital efficiencies from FY28 onwards.
Profitability & Margins
See what Neogen Chemicals said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Neogen Ionics battery chemical CAPEX planned at INR 1,800 crore, with INR 1,300 crore already spent; remaining INR 500 crore expected by FY27 end.
- Incremental CAPEX partly debt-funded and partly equity from Morita (around INR 40-50 crore equity remaining).
- Additional CAPEX for salt and additive capacities planned: 2,000-ton salt capacity at Pakhajan and 500-ton additive capacity at Dahej, requiring ~15 months to build plus approvals.
- Potential capacity ramp-up in organo-lithium segment with minor CAPEX (<INR 15 crore) expected in second half of current year after Board approval.
- Future CSM business capacity expansion possible from FY29-FY30, post clarity on Dahej plant performance.
- INR 600 crore QIP fundraise approved primarily for debt reduction and to fund future growth opportunities, including battery materials and meeting international demand.
- Continuous R&D investment planned for battery performance improvements with novel additives and electrolyte designs.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Neogen Chemicals said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The salt business for the current year is backed by long-term formula-based pricing contracts linked to lithium carbonate pricing, with firm orders already in place.
- All four global customers have audited and approved Neogen's facility.
- Customers are expected to start purchasing gradually in Q2 and Q3 FY27, with full supply from Neogen expected towards the end of Q3 and into Q4.
- Interim sales during Q2-Q3 may include some special pricing, but from Q4 onwards, pricing will follow the contracted formula.
- The contracts are designed to provide stable, consistent pricing rather than fluctuating spot prices.
- No explicit orderbook value is given, but the firm contracted volumes are expected to support 70-80% utilization capacity for salt business in FY27.
Neogen Chemicals — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹247 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Neogen Chemicals Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Solar Industries India Ltd (Q1 FY27)
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Chemicals Ltd (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Frequently Asked Questions
What were Neogen Chemicals Q1 FY27 results?
Base business revenue expected to cross INR 1,000 crore in FY27 with 10-15% growth projected for FY28, targeting INR 1,100-1,200 crore. Revenue Growth**: Base business expected to grow from INR 950-1,050 crore in FY27 to INR 1,100-1,200 crore in FY28, with 10-15% increase focused on stabilizing and optimizing operations.
What is Neogen Chemicals share price analysis?
Neogen Chemicals currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 171.7 with a market cap of ₹6,106 Cr. Investors should review the full earnings analysis for detailed insights.
Is Neogen Chemicals planning capital expenditure?
Neogen Ionics battery chemical CAPEX planned at INR 1,800 crore, with INR 1,300 crore already spent; remaining INR 500 crore expected by FY27 end.
Keep Neogen Chemicals on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.